Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorRischin, Danny
dc.contributor.authorHarrington, Kevin
dc.contributor.authorGreil, Richard
dc.contributor.authorSoulières, Denis
dc.contributor.authorTahara, Makoto
dc.contributor.authorde Castro Junior, Gilberto
dc.contributor.authorBraña Garcia, Irene
dc.date.accessioned2022-08-18T09:13:28Z
dc.date.available2022-08-18T09:13:28Z
dc.date.issued2022-05
dc.identifier.citationRischin D, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro Jr G, et al. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. Oral Oncol. 2022 May;128:105815.
dc.identifier.issn1879-0593
dc.identifier.urihttp://hdl.handle.net/11351/8013
dc.descriptionImmunotherapy; Pembrolizumab; Quality of life
dc.description.abstractObjectives To assess health-related quality of life (HRQoL) with first-line pembrolizumab, pembrolizumab-chemotherapy, or cetuximab-chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the phase 3 KEYNOTE-048 trial (NCT02358031). Materials and Methods HRQoL was measured using the European Organisation for Research and Treatment of Cancer 30-question quality-of-life (EORTC QLQ-C30), the EORTC 35-question quality-of-life head and neck cancer–specific module (EORTC QLQ-H&N35), and the EuroQol 5-dimension 3-level instruments (EQ-5D-3L). Secondary endpoints included mean change from baseline in EORTC QLQ-C30 global health status/quality of life (GHS/QoL) at week 15 and time to deterioration (TTD) in EORTC QLQ-C30 GHS/QoL and EORTC QLQ-H&N35 pain and swallowing. Results Of 882 enrolled participants, 844 received ≥ 1 dose of study treatment and completed ≥ 1 HRQoL assessment; adherence was ≥ 79% at week 15 across treatment groups. At week 15, EORTC QLQ-C30 GHS/QoL scores remained stable; no clinically meaningful between-group differences were observed (least squares mean difference, pembrolizumab vs cetuximab-chemotherapy, 0.24; 95% CI, −3.34 to 3.82; pembrolizumab-chemotherapy vs cetuximab-chemotherapy, 0.40; 95% CI, −3.46 to 4.26). Median TTD in EORTC QLQ-C30 GHS/QoL and EORTC QLQ-H&N35 pain and swallowing scores was not reached over 51 weeks across groups, showing stable HRQoL. TTD was similar between groups for EORTC QLQ-C30 GHS/QoL (pembrolizumab vs cetuximab-chemotherapy: HR, 1.38; 95% CI, 0.95–2.00; pembrolizumab-chemotherapy vs cetuximab-chemotherapy: HR, 1.37; 95% CI, 0.94–2.00), as was TTD in EORTC QLQ-H&N35 pain and swallowing scores. Conclusions Pembrolizumab monotherapy and pembrolizumab-chemotherapy extended OS while maintaining HRQoL, further supporting first-line use for R/M HNSCC.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesOral Oncology;128
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectCap - Càncer - Tractament
dc.subjectColl - Càncer - Tractament
dc.subjectQuimioteràpia combinada
dc.subject.meshSquamous Cell Carcinoma of Head and Neck
dc.subject.mesh/drug therapy
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.titlePembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.oraloncology.2022.105815
dc.subject.decscarcinoma de células escamosas de cabeza y cuello
dc.subject.decs/farmacoterapia
dc.subject.decsprotocolos de quimioterapia antineoplásica combinada
dc.relation.publishversionhttps://doi.org/10.1016/j.oraloncology.2022.105815
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Rischin D] Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia. [Harrington KJ] Radiotherapy and Imaging, The Institute of Cancer Research/The Royal Marsden NHS Foundation Trust, National Institute for Health Research Biomedical Research Centre, London, United Kingdom. [Greil R] Hematology and Medical Oncology, Paracelsus Medical University, Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria. [Soulières D] Haematology/Oncology, Centre Hospitalier de l’Université de Montréal, Montreal, Canada. [Tahara M] Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan. [de Castro G Jr] Medical Oncology, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil. [Braña I] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid35381576
dc.identifier.wos000792907400009
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record